These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 2342197)

  • 41. Contemporary management of superficial bladder cancer.
    Pow-Sang JM; Seigne JD
    Cancer Control; 2000; 7(4):335-9. PubMed ID: 10895127
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin.
    Thalmann GN; Sermier A; Rentsch C; Möhrle K; Cecchini MG; Studer UE
    J Urol; 2000 Dec; 164(6):2129-33. PubMed ID: 11061941
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The effect of liposome encapsulated antineoplastic agents on transitional cell carcinoma in tissue culture.
    Egerdie RB; Reid G; Trachtenberg J
    J Urol; 1989 Aug; 142(2 Pt 1):390-8. PubMed ID: 2501520
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Intravesical sequential combination of epirubicin and interferon alpha-2b in patients affected by superficial transitional cell carcinoma of the bladder. Results of a pilot study at Palermo University and proposal of a basic research.
    Serretta V; Corselli G; Pavone C; Pizzuto Antinoro SA; Pavone-Macaluso M
    Prog Clin Biol Res; 1991; 370():185-93. PubMed ID: 1924449
    [No Abstract]   [Full Text] [Related]  

  • 45. Efficacy of a single intravesical treatment with Ad-IFN/Syn 3 is dependent on dose and urine IFN concentration obtained: implications for clinical investigation.
    Tao Z; Connor RJ; Ashoori F; Dinney CP; Munsell M; Philopena JA; Benedict WF
    Cancer Gene Ther; 2006 Feb; 13(2):125-30. PubMed ID: 16082384
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Treatment of experimental bladder cancer with hyperthermia and phase transition liposomes containing methotrexate.
    Bassett JB; Tacker JR; Anderson RU; Bostwick D
    J Urol; 1988 Mar; 139(3):634-6. PubMed ID: 3343756
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Adjuvant intravesical mitoxantrone versus recombinant interferon-alpha after transurethral resection of superficial bladder cancer: a randomized prospective study.
    Papatsoris AG; Deliveliotis C; Giannopoulos A; Dimopoulos C
    Urol Int; 2004; 72(4):284-91. PubMed ID: 15153724
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Intravesical treatment of bladder cancer with recombinant human interferon-beta. Intravesical GKT-beta Chemotherapy Research Group.
    Niijima T
    Cancer Immunol Immunother; 1989; 30(2):81-5. PubMed ID: 2598181
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Managing superficial bladder cancer: an overview.
    Soloway MS
    Urology; 1992 Dec; 40(6 Suppl):5-10. PubMed ID: 1466119
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of local hyperthermia of the bladder on mitomycin C pharmacokinetics during intravesical chemotherapy for the treatment of superficial transitional cell carcinoma.
    Paroni R; Salonia A; Lev A; Da Pozzo LF; Cighetti G; Montorsi F; Rigatti P; Colombo R
    Br J Clin Pharmacol; 2001 Sep; 52(3):273-8. PubMed ID: 11560559
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Antiviral and antiproliferative properties of liposome-associated human interferon-gamma.
    Smith DM; Mayhew E; Reszka R; Ito M; O'Malley JA
    J Interferon Res; 1990 Apr; 10(2):153-60. PubMed ID: 2111353
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Oncolytic vesicular stomatitis viruses are potent agents for intravesical treatment of high-risk bladder cancer.
    Hadaschik BA; Zhang K; So AI; Fazli L; Jia W; Bell JC; Gleave ME; Rennie PS
    Cancer Res; 2008 Jun; 68(12):4506-10. PubMed ID: 18559493
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Use of intravesical bacillus Calmette-Guérin in the treatment of superficial transitional cell carcinoma of the bladder: an overview.
    Witjes JA; vd Meijden AP; Debruyne FM
    Urol Int; 1990; 45(3):129-36. PubMed ID: 2190404
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Gene therapy by in vivo interferon-gamma gene transfer to murine bladder tumor].
    Hashimura T; Ueda T; Hiura M; Yoshida O; Kawabata K; Watanabe Y; Takami M
    Hinyokika Kiyo; 1997 Nov; 43(11):809-13. PubMed ID: 9436027
    [TBL] [Abstract][Full Text] [Related]  

  • 55. In vivo retroviral mediated gene transfer into bladder urothelium results in preferential transduction of tumoral cells.
    Dumey N; Mongiat-Artus P; Devauchelle P; Lesourd A; Cotard JP; Le Duc A; Marty M; Cussenot O; Cohen-Haguenauer O
    Eur Urol; 2005 Feb; 47(2):257-63. PubMed ID: 15661423
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Sustained intravesical interferon protein exposure is achieved using an adenoviral-mediated gene delivery system: a study in rats evaluating dosing regimens.
    Connor RJ; Anderson JM; Machemer T; Maneval DC; Engler H
    Urology; 2005 Jul; 66(1):224-9. PubMed ID: 15992886
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Intravesial instillation of recombination interferon-alpha and pirarubicin in the prophylaxis of local recurrence after resection of the superficial bladder cancer].
    Deng JH; Bai JL; Zhang SS; Ma PC; Wan JH
    Ai Zheng; 2004 Jul; 23(7):839-41. PubMed ID: 15248924
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder.
    Lamm DL; Blumenstein BA; Crawford ED; Montie JE; Scardino P; Grossman HB; Stanisic TH; Smith JA; Sullivan J; Sarosdy MF
    N Engl J Med; 1991 Oct; 325(17):1205-9. PubMed ID: 1922207
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Antiproliferative and immunomodulatory actions of beta-interferon and double-stranded RNA, individually and in combination, on human bladder tumor xenografts in nude mice.
    Hubbell HR; Kvalnes-Krick K; Carter WA; Strayer DR
    Cancer Res; 1985 Jun; 45(6):2481-6. PubMed ID: 3986788
    [TBL] [Abstract][Full Text] [Related]  

  • 60. High-risk superficial bladder cancer: intravesical therapy for T1 G3 transitional cell carcinoma of the urinary bladder.
    Pham HT; Soloway MS
    Semin Urol Oncol; 1997 Aug; 15(3):147-53. PubMed ID: 9394909
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.